First trimester prediction of ischemic placental disease

Seminars in Perinatology

Volumn 38, Issue 3, 2014, Pages 159-166

  Vintzileos, Anthony M ^a   Ananth, Cande V ^b,c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c Department of Medicine   (United States)

Author keywords

Fetal growth restriction; First trimester; Ischemic placental disease; Placental abruption; Prediction; Preeclampsia

Indexed keywords

ACTIVIN A; ADIPONECTIN; ANGIOPOIETIN 2; CHORIONIC GONADOTROPIN BETA SUBUNIT; INHIBIN A; INTERCELLULAR ADHESION MOLECULE 1; LIOTHYRONINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PENTRAXIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; THYROTROPIN; THYROXINE; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER;

ANEUPLOIDY; CHEMOPROPHYLAXIS; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; DRUG MECHANISM; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC PLACENTAL DISEASE; LIOTHYRONINE BLOOD LEVEL; MEAN ARTERIAL PRESSURE; PLACENTA DISORDER; PREDICTIVE VALUE; PREECLAMPSIA; PREMATURE LABOR; PRENATAL SCREENING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SOLUTIO PLACENTAE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; UMBILICAL ARTERY; UTERINE ARTERY; ABRUPTIO PLACENTAE; DOPPLER FLOWMETRY; ECHOGRAPHY; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; ISCHEMIA; PATHOPHYSIOLOGY; PLACENTA; PLACENTA CIRCULATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURITY; REPRODUCIBILITY; RISK FACTOR; VASCULARIZATION;

ABRUPTIO PLACENTAE; BIOLOGICAL MARKERS; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; ISCHEMIA; PLACENTA; PLACENTAL CIRCULATION; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ULTRASONOGRAPHY, DOPPLER; ULTRASONOGRAPHY, PRENATAL;

EID: 84900434442     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2014.03.006     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention. Available at 〈〉 Accessed 31.12.13. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/UserGuide2010.pdf.
2. Ananth C.V., Joseph K.S., Oyelese Y., Demissie K., Vintzileos A.M. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol 2005, 105(5 Pt 1):1084-1091.
3. Meis P.J., Goldenberg R.L., Mercer B.M., et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol 1998, 178:562-567.
4. Gardner M.O., Goldenberg R.L., Cliver S.P., Tucker J.M., Nelson K.G., Copper R.L. The origin and outcome of preterm twin pregnancies. Obstet Gynecol 1995, 85:553-557.
5. Ananth C.V., Vintzileos A.M. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006, 195:1557-1563.
6. Long P.A., Abell D.A., Beischer N.A. Fetal growth retardation and preeclampsia. BJOG 1980, 87:13-18.
7. Ness R.B., Sibai B.M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006, 195:40-49.
8. Ananth C.V., Peltier M.R., Chavez M.R., Kirby R.S., Getahun D., Vintzileos A.M. Recurrence of ischemic placental disease. Obstet Gynecol 2007, 110:128-133.
9. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol 2011, 204:193-201.
10. Pijnenborg R., Dixon G., Robertson W.B., Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980, 1:3-19.
11. Roberge S., Nicolaides K.H., Demers S., Villa P., Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013, 41:491-499.
12. Bujold E., Roberge S., Lacasse Y., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010, 116(2 Pt 1):402-414.
13. van den Elzen H.J., Cohen-Overbeek T.E., Grobbee D.E., Quartero R.W.P., Wladimiroff J.W. Early uterine artery Doppler velocimetry and the outcome of pregnancy in women aged 35 years and older. Ultrasound Obstet Gynecol 1995, 5:328-333.
14. Harrington K., Goldfrad C., Carpenter R.G., Campbell S. Transvaginal uterine and umbilical artery Doppler examination of 12-16 weeks and the subsequent development of pre-eclampsia and intrauterine growth retardation. Ultrasound Obstet Gynecol 1997, 2:94-100.
15. Martin A.M., Bindra R., Curcio P., Cicero S., Nicolaides K.H. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2001, 18:583-586.
16. Nicolaides K.H., Bindra R., Turan O.M., et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006, 27:13-17.
17. Plasencia W., Maiz N., Bonino S., Kaihura C., Nicolaides K.H. Uterine artery Doppler at 11 + 0 to + 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007, 30:742-749.
18. Parra-Cordero M., Turan O.M., Kaur A., Pearson J.D., Nicolaides K.H. Maternal serum soluble adhesion molecule levels at 11+0+13+6 weeks and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med 2007, 20:793-796.
19. Spencer K., Cowans N.J., Nicolaides K.H. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32:622-626.
20. Spencer K., Cowans N.J., Avgidou K., Molina F., Nicolaides K.H. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008, 31:15-19.
21. Akolekar R., Zaragoza E., Poon L.C.Y., Pepes S., Nicolaides K.H. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32:732-739.
22. Plasencia W., Maiz N., Poon L., Yu C., Nicolaides K.H. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008, 32:138-146.
23. Poon L.C.Y., Maiz N., Valencia C., Plasencia W., Nicolaides K.H. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gyencol 2009, 33:23-33.
24. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53:812-818.
25. Leal A.M., Poon L.C.Y., Frisova V., Venduta A., Nicolaides K.H. First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33:135-141.
26. Akolekar R., Minekawa R., Veduta A., Ximena C., Romero R., Nicolaides K.H. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29:753-760.
27. Akolekar R., Casagrandi D., Skyfta E., Ahmed A.A., Nicolaides K.H. Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29:847-851.
28. Akolekar R., Casagrandi D., Livanos P., Tetteh A., Nicolaides K.H. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29:934-938.
29. Akolekar R., Etchegaray A., Zhou Y., Maiz N., Nicolaides K.H. Maternal serum activin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009, 25:320-327.
30. Staboulidou I., Galindo A., Maiz N., Karagiannis G., Nicolaides K.H. First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-A in preeclampsia and chromosomal defects. Fetal Diagn Ther 2009, 25:336-339.
31. Akolekar R., deCruz J., Foidart J.M., Munaut C., Nicolaides K.H. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn 2010, 30:191-197.
32. Ashoor G., Maiz N., Rotas M., Kametas A., Nicolaides K.H. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia. Prenat Diagn 2010, 30:1032-1038.
33. Sifakis S., Akolekar R., Kappou D., Mantas N., Nicolaides K.H. Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia. Prenat Diagn 2010, 30:1026-1031.
34. Karagiannis G., Akolekar R., Sarquis R., Wright D., Nicolaides K.H. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2010, 11:1-7.
35. Sifakis S., Akolekar R., Kappou D., Mantas N., Nicolaides K.H. Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia. Prenat Diagn 2011, 31:196-201.
36. Nanda S., Yu C.K.H., Giurcaneanu L., Akolekar R., Nicolaides K.H. Maternal serum adiponectin at 11-13 weeks of gestation in preeclampsia. Fetal Diagn Ther 2011, 29:208-215.
37. Sifakis S., Akolekar R., Mantas N., Kappou D., Nicolaides K.H. Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia. Hypertens Pregnancy 2011, 30:74-82.
38. Plasencia W., Akolekar R., Dagklis T., Venduta A., Nicolaides K.H. Placental volume at 11-13 weeks' gestation in the prediction of birth weight percentile. Fetal Diagn Ther 2011, 30:23-28.
39. Ertl R., Yu C.K.H., Samaha R., Akolekar R., Nicolaides K.H. Maternal serum vitamin D at 11-13 weeks in pregnancies delivering small for gestational age neonates. Fetal Diagn Ther 2012, 31:103-108.
40. Sifakis S., Akolekar R., Kappou D., Mantas N., Nicolaides K.H. Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia. J Hum Hypertens 2012, 26:253-258.
41. Wright D., Akolekar R., Syngelaki A., Poon L.C.Y., Nicolaides K.H. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 2012, 32:171-178.
42. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. Competing risk model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013, 33:8-15.
43. Ferreira A.F., Rezende J.C., deCassia C., Oliveira R., Akolekar R., Nicolaides K.H. Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia. J Hum Hypertens 2013, 27:261-264.
44. Poon L.C.Y., Syngelaki A., Akolekar R., Lai J., Nicolaides K.H. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013, 33:16-27.
45. Pilalis A., Souka A.P., Antsaklis P., Daskalakis G., Papantoniou N., Mesogitis S., et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation. Ultrasound Obstet Gynecol 2007, 29:135-140.
46. Lefebvre J., Demers S., Bujold E., et al. Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks. Ultrasound Obstet Gynecol 2012, 40:288-292.
47. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy (Collaborators 22). Obstet Gynecol 2013, 122:1122-1131.